Abstract |
The commonly used inactivated or split influenza vaccines induce only induce minimal T cell responses and are less effective in preventing heterologous virus infection. Thus, developing cross-protective influenza vaccines against the spread of a new influenza virus is an important strategy against pandemic emergence. Here we demonstrated that immunization with heat shock protein gp96 as adjuvant led to a dramatic increased antigen-specific T cell response to a pandemic H1N1 split vaccine. Notably, gp96 elicited a cross-protective CD8(+) T cell response to the internal conserved viral protein NP. Although the split pH1N1vaccine alone has low cross-protective efficiency, adding gp96 as an adjuvant effectively improved the cross-protection against challenge with a heterologous virus in mice. Our study reveals the novel property of gp96 in boosting the T cell response against conserved epitopes of influenza virus and its potential use as an adjuvant for human pre-pandemic inactivated influenza vaccines against different viral subtypes.
|
Authors | Ying Ju, Hongxia Fan, Jun Liu, Jun Hu, Xinghui Li, Changfei Li, Lizhao Chen, Qiang Gao, George F Gao, Songdong Meng |
Journal | Vaccine
(Vaccine)
Vol. 32
Issue 23
Pg. 2703-11
(May 13 2014)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 24699472
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 Elsevier Ltd. All rights reserved. |
Chemical References |
- Adjuvants, Immunologic
- Antibodies, Viral
- Heat-Shock Proteins
- Influenza Vaccines
|
Topics |
- Adjuvants, Immunologic
(pharmacology)
- Animals
- Antibodies, Viral
(blood)
- CD8-Positive T-Lymphocytes
(immunology)
- Cross Protection
- Female
- Heat-Shock Proteins
(pharmacology)
- Hemagglutination Inhibition Tests
- Immunity, Cellular
- Immunity, Humoral
- Influenza A Virus, H1N1 Subtype
- Influenza Vaccines
(immunology)
- Mice, Inbred BALB C
- Neutralization Tests
- Orthomyxoviridae Infections
(prevention & control)
|